/TECX
TECX Stock - Tectonic Therapeutic, Inc.
Healthcare|BiotechnologyNASDAQ
$19.88+1.43%
+$0.28 (+1.43%) • Jan 13
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.53
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.57
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+201.8%upside
Target: $60.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TECX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$19.68 – $20.08
TARGET (TP)$60.00
STOP LOSS$18.29
RISK/REWARD1:25.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.58
52W High$61.07
52W Low$13.70
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | $-1,207,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-58,015,000 | $-44,648,000 | $-32,830,000 | $-15,610,000 | $-120,228,000 |
| Net Income | $-57,982,000 | $-42,823,000 | $-32,180,000 | $-8,927,000 | $-119,712,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-3.93 | $-11.59 | $-29.05 | $-33.36 | $-39.68 |
Company Overview
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
6 Bullish0 Neutral/Bearish
Price Targets
$70
Average Target
↑ 253.5% Upside
Now
$51
Low
$70
Average
$101
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 20th 2025 | Wells Fargo | Initiation | Overweight | $101 |
| September 3rd 2025 | Oppenheimer | Initiation | Outperform | $80 |
| July 21st 2025 | Truist | Initiation | Buy | $64 |
| June 11th 2025 | Raymond James | Resumed | Outperform | $76 |
| April 21st 2025 | Mizuho | Initiation | Outperform | $51 |
| November 20th 2024 | Raymond James | Initiation | Outperform | $65 |
| August 22nd 2024 | Wells Fargo | Initiation | Overweight | $55 |
| June 26th 2024 | Piper Sandler | Initiation | Overweight | - |
| June 24th 2024 | TD Cowen | Initiation | Buy | - |
Earnings History & Surprises
TECXBeat Rate
50%
Last 14 quarters
Avg Surprise
+22.7%
EPS vs Estimate
Beats / Misses
7/7
Last 12 quarters
Latest EPS
$-1.02
Q4 2025
EPS Surprise History
Q1 24
+40.6%
$-2.40vs$-4.04
Q2 24
+58.3%
$-1.80vs$-4.32
Q3 24
-94.4%
$-3.81vs$-1.96
Q4 24
-42.9%
$-1.20vs$-0.84
Q1 25
+39.6%
$-0.84vs$-1.39
Q2 25
+15.5%
$-0.93vs$-1.10
Q3 25
-9.2%
$-1.07vs$-0.98
Q4 25
+2.9%
$-1.02vs$-1.05
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 19, 2026 | $-1.11 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-1.05 | $-1.02 | +2.9% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.98 | $-1.07 | -9.2% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-1.10 | $-0.93 | +15.5% | ✓ BEAT |
Q1 2025 | Mar 20, 2025 | $-1.39 | $-0.84 | +39.6% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.84 | $-1.20 | -42.9% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-1.96 | $-3.81 | -94.4% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-4.32 | $-1.80 | +58.3% | ✓ BEAT |
Q1 2024 | Mar 14, 2024 | $-4.04 | $-2.40 | +40.6% | ✓ BEAT |
Q3 2023 | Sep 29, 2023 | $-4.22 | $-5.81 | -37.7% | ✗ MISS |
Q2 2023 | Jun 29, 2023 | $-6.49 | $18.29 | +381.8% | ✓ BEAT |
Q1 2023 | Mar 30, 2023 | $-6.45 | $-6.80 | -5.5% | ✗ MISS |
Q4 2022 | Dec 31, 2022 | $-5.91 | $-6.86 | -16.0% | ✗ MISS |
Q3 2022 | Sep 29, 2022 | $-6.60 | $-6.30 | +4.6% | ✓ BEAT |
Q2 2022 | Jun 29, 2022 | — | $-7.70 | — | — |
Q1 2022 | Mar 30, 2022 | $-6.87 | $-8.19 | -19.3% | ✗ MISS |
Q4 2021 | Dec 30, 2021 | — | $-7.76 | — | — |
Q3 2021 | Sep 29, 2021 | — | $-8.97 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.74 | — | — |
Latest News
Truist Securities Maintains Buy on Tectonic Therapeutic, Lowers Price Target to $60
➖ NeutralBenzinga•Jan 8, 2026, 05:23 PM
Tectonic Therapeutic Q3 EPS $(1.02) Beats $(1.05) Estimate
📈 PositiveBenzinga•Nov 6, 2025, 10:07 PM
TECX stock has given up its prior gain. Tectonic Therapeutic shares were trading higher after the company announced topline results from the Phase 1b Part B acute hemodynamic clinical trial of TX45 in patients with Group 2 PH‑HFrEF.
📉 NegativeBenzinga•Oct 30, 2025, 07:36 PM
Tectonic Therapeutic shares are trading higher after the company announced topline results from the Phase 1b Part B acute hemodynamic clinical trial of TX45 in patients with Group 2 PH‑HFrEF.
📈 PositiveBenzinga•Oct 30, 2025, 11:22 AM
Tectonic surges on phase 1b data for pulmonary hypertension asset
📈 PositiveSeeking Alpha•Oct 29, 2025, 09:21 PM
Tectonic Therapeutic shares are trading higher after the company announced topline results from the Phase 1b Part B acute hemodynamic clinical trial of TX45 in patients with Group 2 PH‑HFrEF.
📈 PositiveBenzinga•Oct 29, 2025, 08:37 PM
Trading Halt: Halt status updated at 4:25:00 PM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Oct 29, 2025, 08:25 PM
Tectonic Therapeutic Reports Phase 1b Part B Clinical Trial Data For TX45 In Patients With Group 2 Pulmonary Hypertension In HFrEF
➖ NeutralBenzinga•Oct 29, 2025, 08:03 PM
Trading Halt: Halted at 4:00:10 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Oct 29, 2025, 08:00 PM
Oppenheimer Initiates Coverage On Tectonic Therapeutic with Outperform Rating, Announces Price Target of $80
📈 PositiveBenzinga•Sep 3, 2025, 04:36 PM
Frequently Asked Questions about TECX
What is TECX's current stock price?
Tectonic Therapeutic, Inc. (TECX) is currently trading at $19.88 per share. The stock has moved +1.43% today.
What is the analyst price target for TECX?
The average analyst price target for TECX is $60.00, based on 1 analyst.
What sector is Tectonic Therapeutic, Inc. in?
Tectonic Therapeutic, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is TECX's market cap?
Tectonic Therapeutic, Inc. has a market capitalization of $0.37 billion, making it a small-cap company.
Does TECX pay dividends?
No, Tectonic Therapeutic, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACIU
AC Immune S.A.
$3.65
Mkt Cap: $0.4B
ALDX
Aldeyra Therapeutics, Inc.
$4.04
Mkt Cap: $0.2B
AMRN
Amarin Corporation plc
$15.47
Mkt Cap: $0.3B
ANRO
Alto Neuroscience, Inc.
$15.90
Mkt Cap: $0.5B
CLLS
Cellectis S.A.
$4.22
Mkt Cap: $0.4B
DBVT
DBV Technologies S.A.
$17.04
Mkt Cap: $0.4B
DRTS
Alpha Tau Medical Ltd.
$6.55
Mkt Cap: $0.6B
LRMR
Larimar Therapeutics, Inc.
$3.36
Mkt Cap: $0.3B
LYEL
Lyell Immunopharma, Inc.
$24.37
Mkt Cap: $0.5B
SLN
Silence Therapeutics plc
$5.85
Mkt Cap: $0.3B
Explore stocks similar to TECX for comparison